Discover open access scientific publications

Search, annotate, share and cite publications

Publications by H. Linardou

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-61 EGFR and KRAS Mutational Status and Significance in Greek Patients With Advanced Non Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Related publications

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC With PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2020English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy